Phase I Dose Escalation Study of ON 01910.Na by 3-day Continuous Infusion in Patients With Advanced Cancer
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Rigosertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Onconova Therapeutics
- 20 Feb 2012 Actual end date (January 2012) added as reported by ClinicalTrials.gov.
- 20 Feb 2012 Actual initiation date (August 2006) and actual patient no 29 added as reported by ClinicalTrials.gov.
- 20 Feb 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).